Selecting Hypoxic Tumours for Treatment Modification in Bladder, Prostate, and Cervical Cancers

What this Trial Is About

Researchers are investigating whether personalized treatment guided by hypoxia biomarkers can improve outcomes for patients with certain solid tumors, including bladder, prostate, and cervical cancers. Hypoxic tumors, which have low oxygen levels, tend to respond poorly to radiotherapy and are linked to worse prognosis. This study focuses on demonstrating that gene-expression signature biomarkers can identify hypoxic tumors and predict which patients will benefit from hypoxia modification treatments during radiotherapy in real-time. The study includes patients diagnosed with bladder, prostate, or cervical cancer who are receiving radiotherapy and can undergo MRI scans. The research integrates gene-expression biomarkers from tumor tissue with advanced MRI techniques to assess tumor hypoxia more accurately. This personalized approach aims to guide treatment modifications such as oxygen-enriched air breathing, nicotinamide administration, chemoradiosensitisation, or radiation dose escalation. The study also explores combining radiological data with biomarkers and evaluating blood-based biomarkers as early indicators of treatment response. Participants will undergo MRI imaging and provide tumor tissue samples for gene-expression analysis to assess hypoxia status before and during radiotherapy. Researchers will monitor treatment response and survival outcomes up to May 2028, integrating imaging and biomarker data to personalize therapy. Safety assessments include screening for MRI contraindications and pregnancy status. The study is observational and involves regular follow-up and data collection to evaluate the predictive value of hypoxia biomarkers and imaging in guiding cancer treatment.

Selecting Hypoxic Tumours for Treatment Modification